Jennifer L. LaPerle
Pfizer (United States)(US)
Publications by Year
Research Areas
Lipid metabolism and biosynthesis, Pancreatic function and diabetes, Drug Transport and Resistance Mechanisms, Diet, Metabolism, and Disease, Epilepsy research and treatment
Most-Cited Works
- → THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL(2004)440 cited
- → A comprehensive non‐clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder(2011)178 cited
- → Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1(2011)102 cited
- → An Analytical Method for the Analysis of Tulathromycin, an Equilibrating Triamilide, in Bovine and Porcine Plasma and Lung(2004)52 cited
- → Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment(2015)42 cited
- → Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans(2013)37 cited
- → Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core(2011)22 cited
- → Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor(2013)21 cited
- → Impact of Time-Dependent Inactivation on the Estimation of Enzyme Kinetic Parameters for Midazolam(2009)3 cited
- → Corrigendum to “Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor” [Bioorg. Med. Chem. 21 (2013) 5081–5097](2013)1 cited